Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2026-02-21 @ 11:17 PM
Study NCT ID:
NCT06430866
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2024-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Sponsor:
Amgen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
20230127
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None